Adaptimmune Therapeutics
#10094
Rank
$21.18M
Marketcap
United Kingdom
Country
Mr. Adrian G. Rawcliffe (CEO, Principal Accounting Officer & Director)
Dr. Helen Katrina Tayton-Martin MBA, Ph.D. (Co-Founder & Chief Bus. & Strategy Officer)
Mr. Gavin Hilary James Wood BA (Hons), ACA (Chief Financial Officer)
Summary
History
Adaptimmune was founded in 2008, launching one of the first clinical trials to test the safety of an approach known as TCR-T therapy. TCR-T therapy involves taking T-cells from a patient’s blood, genetically engineering them to recognize cancer cells, and infusing them back into the patient. Adaptimmune’s breakthroughs over the past decade have proven the efficacy of their approach, and the company is now working to improve the capabilities of their therapies, with the goal of becoming an industry leader in T-cell therapy for cancer treatments.
Mission
Vision
Key Team
Mr. William C. Bertrand Jr., Esq., J.D. (Chief Operating Officer)
Mr. John Lunger (Chief Patient Supply Officer)
Ms. Joanna Brewer Ph.D. (Chief Scientific Officer)
Dr. Juli P. Miller Ph.D. (VP of Investor Relations)
Ms. Kerry Sharp (Sr. VP & Gen. Council)
Ms. Margaret Henry (Head of PR & Company Sec.)
Mr. Sébastien Desprez (VP of Communications & Corp. Affairs)
Recognition and Awards
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Mr. Adrian G. Rawcliffe (CEO, Principal Accounting Officer & Director)
Dr. Helen Katrina Tayton-Martin MBA, Ph.D. (Co-Founder & Chief Bus. & Strategy Officer)
Mr. Gavin Hilary James Wood BA (Hons), ACA (Chief Financial Officer)